Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Tislelizumab + Chemotherapy Followed by Adjuvant Tislelizumab for the Treatment of Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

NCT05211232 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05211232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05211232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Tislelizumab + Chemotherapy Followed by Adjuvant Tislelizumab for the Treatment of Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 10, 2022
Completion date
June 2, 2028
Enrollment
450 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma